title: Oncogenic receptor tyrosine kinase in leukemia.
abstract: Growth, survival and differentiation of hematopoietic cells are regulated by the interaction between hematopoietic growth factors and their receptors. While the defect in this interaction results in an insufficient hematopoiesis, the aberrantly elevated activation leads to the transformation of hematopoietic cells. The constitutive active mutations of receptor tyrosine kinase, such as c-Kit platelet-derived growth factor receptor (PDGFR) or fins-like tyrosine kinase 3 (Flt3), play a major role in the development of hematopoietic neoplasia. The constitutive activation is provoked by several mechanisms, such as making fusion genes by chromosomal translocations, or various mutations involving regulatory regions of the receptor. The chromosomal translocation brings the receptor intracytoplasmic domain juxtaposed to an unrelated molecule which has dimerization or multimerization motif, resulting in the constitutive dimerization of the receptor. The missense, insertion or deletion mutations in the regulatory regions, such as juxtamembrane domain, activation loop and extracellular domain, cause constitutive activation by releasing the respective auto-inhibitory functions of each regulatory region. Constitutive active receptors generate different signals quantitatively and qualitatively from wild type receptor, which mediate the oncogenic phenotype. Given the frequent involvement of constitutive active receptor tyrosine kinase in hematopoietic malignancies, targeted inhibitions of active tyrosine kinase and downstream aberrant signaling are rapidly developing novel therapeutic modality with much promise.
authors.affiliation: Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, 565-0871, Osaka, Japan. mizuki@bldon.med.osaka-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Mizuki
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.forename: I
authors.initials: I
authors.lastname: Matsumura
authors.forename: J
authors.initials: J
authors.lastname: Ishiko
authors.forename: J
authors.initials: J
authors.lastname: Schwäble
authors.forename: H
authors.initials: H
authors.lastname: Serve
authors.forename: Y
authors.initials: Y
authors.lastname: Kanakura
mesh_terms: D000818:Animals; D006801:Humans; D007938:Leukemia / Q000201:enzymology* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D015514:Oncogene Proteins, Fusion; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases; D020796:Receptor, Platelet-Derived Growth Factor alpha; D051941:fms-Like Tyrosine Kinase 3